EVG.L - Evgen Pharma plc

LSE - LSE Delayed price. Currency in GBp
20.10
-0.15 (-0.74%)
As of 11:16AM BST. Market open.
Stock chart is not supported by your current browser
Previous close20.25
Open20.25
Bid20.00 x 0
Ask0.00 x 0
Day's range20.10 - 20.25
52-week range13.10 - 33.00
Volume57,408
Avg. volume566,823
Market cap22.522M
Beta (3Y monthly)1.38
PE ratio (TTM)N/A
EPS (TTM)-3.00
Earnings date4 Dec 2017 - 8 Dec 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est113.00
  • Simply Wall St.6 months ago

    Does Evgen Pharma plc (LON:EVG) Have A High Beta?

    Anyone researching Evgen Pharma plc (LON:EVG) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there Read More...

  • EQS Group11 months ago

    Hardman & Co Research: Evgen Pharma (EVG): 2018, a pivotal year

    EVG is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. EVG has created new and stable variants of sulforaphane using its proprietary technology, Sulforadex, enabling it to be used as a therapeutic for the first time. SFX-01 is currently in Phase II trials for both subarachnoid haemorrhage and ER+ metastatic breast cancer, with read-outs expected around the end of 2018.

  • EQS Group11 months ago

    Hardman & Co Research: Evgen Pharma (EVG): Encouraging interim data from the STEM trial

    Evgen (EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. EVG has created new and stable variants of sulforaphane using its proprietary technology, Sulforadex, enabling it to be used as a therapeutic for the first time. SFX-01 is currently in Phase II trials for both subarachnoid haemorrhage (SAH) and ER+ breast cancer, with read-outs expected around the end of 2018.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes